1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>France

France Invites Advanced Therapy Makers To Use Fast-Track Trial Approval Pathway

 
• By Neena Brizmohun

Updated guidance on France’s experimental fast-track procedure for approving clinical trials shows that the pathway has entered a new phase.

Train
French regulators are speeding up approvals for advanced therapy trials. • Source: Shutterstocks

The French regulatory agency, ANSM, has now opened up its experimental fast-track pathway for approving clinical trials to sponsors developing advanced therapy medicinal products (ATMPs), according to an updated guide on how to use the rapid authorization process.

The voluntary pathway, which ANSM began testing last year for other types of medicinal products, may be used by ATMP...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from France

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

French Bill Could Improve Clinical Research, But Further Action Is Required

 
• By Francesca Bruce

France’s simplification bill is a “first step” to improving the country’s clinical research environment, but more could be done to drive decentralized trials and simplify processes, says Leem, the French pharmaceutical industry association.

France’s New Carbon Footprint Measuring Method Could Guide Purchasing Decisions

 
• By Francesca Bruce

A new methodology for measuring pharmaceutical company carbon footprints could lead to a single standard for producing these calculations that is applicable to all medicines sold in France, said the industry association, Leem. However, it warned that there remains uncertainty about how the methodology will work in practice.

France Finally Passes Price Cutting Finance Bill – With Some Amendments

 
• By Francesca Bruce

Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.

More from Europe

Trial Cancellations And Delays Persist For CROs Amid Biotech Slowdown

 
• By Vibha Sharma

The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 
• By Neena Brizmohun

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.